All About Adult Hodgkin Lymphoma
What are lymph nodes?
Lymph nodes are small, bean-sized glands that are found throughout the body and makeup part of the lymphatic fluid circulation system. Lymphatic fluid is a clear fluid that leaks out of blood vessels. In order for the body to keep the blood volume constant, lymphatic fluid is collected and returned to the blood via the lymphatic circulation. Lymph nodes are connected to each other by small lymph vessels that move the lymphatic fluid.
Before returning the lymphatic fluid to the blood, lymph nodes clean the fluid, looking for possible infection-causing germs (bacteria, viruses, etc.). Most people can remember having swollen "glands" under their neck when they had an infection. Those "glands" were swollen lymph nodes that were reacting to the infection. In most cancers, this network of lymph nodes is one of the first areas to which cancer can spread. However, in Hodgkin lymphoma, the cancer arises from the lymph nodes themselves.
Clusters of lymph nodes exist in certain parts of the body, like the neck, the underarm, and the groin. There are also specific organs in the body that are considered part of the lymphatic system, like the spleen and the tonsils. Small amounts of lymph tissue can also be found in almost every other organ in the body. While there are certain areas in the body where lymph nodes are often found, the arrangement and number of these lymph nodes is different from person to person.
What is Hodgkin Lymphoma?
Hodgkin lymphoma is a cancer of lymph nodes and lymphatic tissue. It is named after the pathologist who first described the disease in 1832, Dr. Thomas Hodgkin. There are about 8,110cases of Hodgkin lymphoma diagnosed yearly in the United States. Hodgkin lymphoma occurs slightly more in men and much more frequently in Caucasians and Hispanic men. Hodgkin lymphoma most commonly affects people ages 15 to 40 (especially those in their 20s) and those over the age of 55 (Pediatric Hodgkin lymphoma is discussed separately).
There are other types of lymphomas besides Hodgkin lymphoma, known as non-Hodgkin lymphomas. Although non-Hodgkin lymphomas are also a cancer of the lymph nodes, they act differently and are treated differently. Hodgkin lymphoma occurs when infection-fighting cells in the lymph nodes begin to grow out of control and compress nearby tissues or spread throughout the body via the lymphatic circulation. Hodgkin lymphoma is distinguished from the other types of lymphomas by the way it looks under a microscope and by the way it grows and spreads.
There are two main types of Hodgkin lymphoma: classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin disease. There are four subtypes of the classical type:
- Nodular sclerosing (70%).
- Mixed cellularity (20-25%).
- Lymphocyte-depleted (5%).
- Lymphocyte-rich (<1%).
Overall, classical Hodgkin lymphoma accounts for about 95% of all cases, while nodular lymphocyte-predominant (NLP) Hodgkin lymphoma is quite rare. The type of Hodgkin lymphoma a person has is determined by a pathologist, who tests a portion of tissue of the involved node(s). Pathologists look for a particular abnormal cell known as a Reed-Sternberg cell (also known as an "owl's eye" cell) in order to diagnose classic Hodgkin lymphoma, or a "popcorn" cell to diagnose NLP Hodgkin lymphoma. The distinction between classical Hodgkin and NLP is important because they are treated differently.
What causes Hodgkin Lymphoma and am I at risk?
No one knows what causes Hodgkin lymphoma. Several factors have been linked with Hodgkin lymphoma. It is important to note that these factors may increase the risk of developing Hodgkin lymphoma, but that the majority of people with these conditions still do not develop Hodgkin lymphoma.
- Epstein-Barr Virus: Infection with the Epstein-Barr virus may play a role in the development of certain types of Hodgkin lymphoma. Epstein-Barr virus also causes mononucleosis, also known as "mono" or "kissing disease."
- Family History: It appears that the relatives of people who develop Hodgkin lymphoma at a very young age may be at increased risk of developing Hodgkin lymphoma.
- HIV Infection: People with depressed immune function, such as patients with HIV/AIDS or those taking medications that suppress the immune system (for example, people with organ transplants or autoimmune diseases), appear to be at higher risk of developing Hodgkin lymphoma. Hodgkin lymphoma in HIV-infected patients is generally more aggressive and advanced than in non-HIV-infected patients.
How can I prevent Hodgkin lymphoma?
Because no one knows exactly what causes Hodgkin lymphoma, there are no specific steps you can take to prevent it.
What screening tests are used for Hodgkin lymphoma?
Hodgkin lymphoma is rare enough that it is not screened for in the general population with any specific blood tests or radiology studies. The best way to detect Hodgkin lymphoma early is to see your healthcare provider regularly for a thorough physical examination. Often, the patient is the first to notice a lump, and if this happens, you should see your healthcare provider for examination and further evaluation.
What are the signs of Hodgkin lymphoma?
The early stages of Hodgkin lymphoma often do not cause any symptoms. As the tumor grows in size it can produce a variety of symptoms. The most common lymph node site affected by Hodgkin lymphoma is in the neck, and neck swelling is what often brings people to the healthcare provider. However, Hodgkin lymphoma can also cause swelling of the lymph nodes in the underarm, upper chest, abdomen, or groin. These swellings are often not painful but can feel rubbery. Hodgkin lymphoma can also cause fevers, drenching night sweats, fatigue, weight loss, and even generalized itching.
If the Hodgkin lymphoma is affecting the lymph nodes in the chest, which are not typically seen or felt, the swelling can cause symptoms such as cough, shortness of breath, or chest pain. A chest x-ray can often show these swollen nodes in the chest. Some people with Hodgkin lymphoma will note pain in the lymph nodes after minimal alcohol consumption.
Many of these symptoms are non-specific, and could represent a variety of different conditions; however, your healthcare provider needs to see you if you have any of these problems.
How is Hodgkin lymphoma diagnosed?
When a patient presents with symptoms suggestive of Hodgkin lymphoma, their healthcare provider will perform a thorough history and physical examination. If there is a node that is enlarged, it will likely be surgically removed in what is called an excisional biopsy. Either part of or the entire node is removed so that a doctor, called a pathologist, can look at it under a microscope. A biopsy specimen is required to make the diagnosis of Hodgkin lymphoma. It is important that the provider use an excisional biopsy–the alternative is a core-needle biopsy, where a small needle is inserted into the swollen lymph node and a sample of the lymph node is taken. However, core-needle biopsies may not provide enough tissue to make a diagnosis.
Once the diagnosis is made, a healthcare provider will order a number of tests to get a sense of the extent and severity of the disease. A few different blood tests will probably be ordered, including blood counts, liver function tests, kidney function tests, erythrocyte sedimentation rate (ESR, a marker of inflammation), and a pregnancy test in women of childbearing age.
Your healthcare provider will also order a PET-CT scan to see the extent of the disease. A PET-CT scan combines a CT scan of the body (a 3D x-ray) with PET. The CT portion helps define the location of lymph nodes that are affected by cancer. The PET scan is a special type of scan where a sugar solution is injected through an IV. Tissues that are very active (like cancer cells) use the sugar for energy. These areas "light up" when they are scanned. The PET scan is important for two reasons: 1) It helps confirm where lymphoma is located in the body; and 2) It gives your provider the "before-treatment" picture. PET scan is used after treatment to be able to compare the "after-treatment" PET with a "before-treatment" PET.
You may have a bone marrow aspiration and biopsy done to determine if the disease is in your bone marrow. You may have a number of other tests depending on the symptoms you are having. These tests include an echocardiogram to check your heart function, pulmonary function tests to check the function of your lungs, X-rays, CT scans, and MRIs. Your provider will determine which of these tests are necessary.
How is Hodgkin lymphoma staged?
After your full workup is complete your care team will stage your cancer. Staging is important because it classifies your cancer by how much disease you have and if/where it has spread. Staging helps guide your treatment plan. The staging system for Hodgkin lymphoma is known as the Cotswold system. It has four different stages:
- Stage I: Also known as early stage. A single lymph node region is involved.
- Stage II: Also known as locally advanced disease. Two or more lymph node regions involved on the same side of the diaphragm (the muscle that controls breathing and that separates the chest from the abdomen) or one lymph node region plus a nearby area or organ. If the disease involves a nearby area or organ it is classified as "E" disease or "extension."
- Stage III: Also known as advanced disease. Lymph nodes above and below the diaphragm are involved, or one node area and one organ on the opposite side of the diaphragm. Disease involving one node area and one organ on the opposite side of the diaphragm is "E" disease.
- Stage IV: Also known as widespread disease. The lymphoma has spread outside the lymph nodes and spleen and into one or more other areas of the body including the bone, bone marrow, skin, and organs.
Early-stage Hodgkin lymphoma (Stage I-II) is divided further into two groups, "favorable" and "unfavorable," to help predict which patients may benefit from more aggressive treatment. The criteria for unfavorable disease are as follows:
- Bulky disease (tumor >10 cm in size).
- Extension outside of lymph nodes ("extranodal" disease).
- Involvement of three or more lymph node areas, or ESR > 50 mm. The erythrocyte sedimentation rate (ESR) is a laboratory test that measures the rate at which red blood cells sediment in a period of one hour.
Your cancer staging may also include letters. Explanations are as follows:
- E: There is an extension of the disease affecting an organ outside of the lymph system.
- S: The disease involves the spleen.
- B: The patient has presented with "B" symptoms related to the disease including: loss of more than 10% of body weight over the past 6 months, fever of 100.4 F or higher or night sweats.
- A: The patient has had no "B" symptoms.
- X: The patient has bulky disease. Bulky disease is disease that describes tumors in the chest that are at least one third as wide as the chest.
Some other terms used when describing Hodgkin lymphoma are "resistant" or "progressive" disease. These terms are used when treatment does not make the disease go away or the disease gets worse. "Recurrent" or "relapsed" disease is the term used when the disease went away with treatment, but has returned in either the same place or in another part of the body.
How is Hodgkin lymphoma treated?
The treatment plan chosen depends on the stage of the disease and the patient's current health status. The treatment plan should be developed by a provider who specializes in the treatment of lymphomas. The type and duration of treatment depend on the stage of Hodgkin lymphoma, whether it is favorable or unfavorable, and if it is NLP Hodgkin.
The two standards of treatment for Hodgkin lymphoma are chemotherapy and radiation. Hodgkin lymphoma can also be treated with multimodal therapy (combination of therapies), which includes chemotherapy, radiation and stem cell transplant. Other therapies may include targeted therapy or clinical trials.
Chemotherapy is the use of medications that treat cancer. Chemotherapy is known as a "systemic" treatment, which means that it goes throughout the entire body. These medications may be given through a vein (IV, intravenously) or by mouth, as pills. Chemotherapy is frequently used to treat Hodgkin lymphoma, and combinations of different chemotherapy medications are typically used to kill the tumor cells. Some chemotherapy regimens may be given prior to treatment with radiation. The most common chemotherapy regimens used are called ABVD, BEACOPP, and Stanford Five (V).
- ABVD: adriamycin, bleomycin, vinblastine, and dacarbazine.
- BEACOPP: bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone.
- Stanford V: doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone.
You may receive one of these regimens or a combination of other medications. It is not always clear that one chemotherapy regimen is better than the others. The regimen selected may vary between providers. Your provider can explain why they recommend one particular regimen over another.
The most common targeted therapy used in the treatment of Hodgkin lymphoma, especially in the treatment of NDL, is rituximab (Rituxan®). Rituximab can be given by itself or in combination with chemotherapy and/or radiation. Brentuximab vedotin is often used for patients whose disease has returned after other treatment regimens. Other targeted therapies used in the treatment of relapsed or refractory Hodgkin lymphoma include everolimus, nivolumab, and pembrolizumab.
Because of the potential risk to fertility associated with chemotherapy medications used to treat Hodgkin lymphoma, discuss fertility preservation options with your healthcare provider before starting treatment.
Radiation therapy uses high-energy rays (similar to x-rays), delivered from an external source, to kill cancer cells. Unlike chemotherapy, which goes everywhere in the body, radiation therapy is a local treatment. It targets small areas. There are two main types of radiation used to treat Hodgkin lymphoma: photon (traditional radiation) and proton therapy. Proton therapy is only available at a certain centers. You should discuss with your provider which type of radiation therapy is right for you.
Radiation therapy has evolved in the last few decades, as concern has grown over the long-term effects of radiation on important organs, like the heart and lungs. For this reason, when possible, radiation is avoided. In patients who need radiation, there is considerable effort made to protect the surrounding healthy tissue. Advanced radiation techniques and methods, such as IMRT, respiratory gating, breath-holding, and advanced simulation techniques (4D imaging), allow for highly conforming doses. This means the radiation beams are shaped tightly around the tumor and spare surrounding tissue as much as possible.
In addition, the area treated has evolved over time. Many radiation oncologists now choose to treat just the lymph nodes that are involved and the surrounding areas where the tumor had spread (called involved site radiation therapy, ISRT). This has largely replaced treating an entire field around the involved lymph nodes (involved field radiation therapy). In the past, even larger fields were treated, including large areas of healthy tissue (called extended field radiation therapy).
Radiation therapy typically requires patients to come to a radiation therapy treatment center 5 days a week, for several weeks. The radiation team will take scans and measurements to determine the number of doses needed and exactly where the radiation beams should be aimed. The treatment takes just a few minutes, and it is painless. You shouldn't feel anything, though you may see some lights on the machines and hear them as they move around. Most radiation providers see patients weekly while they are receiving treatment to monitor for side effects and answer questions.
Stem Cell Transplant
Sometimes patients receive chemotherapy and/or radiation therapy, but the Hodgkin lymphoma is still present (also known as refractory Hodgkin lymphoma). When this happens, the provider may recommend stem cell transplantation (SCT). Stem cells are precursor cells that can develop into other cells of the body when placed in the right environment. In the case of SCT, the stem cells used are pre-destined to become blood cells (white and red blood cells or platelets).
Stem cell transplant is used along with high doses of chemotherapy. The high doses of chemotherapy are given with the intent to wipe out a person's bone marrow. Without bone marrow, a person can't make the components of blood and the immune system that are necessary to survive. In order to replace the patient's bone marrow, stem cells are given. In the case of an autologous stem cell transplants, a patient's own stem cells are harvested (collected) before the high dose chemotherapy is given. These cells are stored and then finally returned to the patient after the chemotherapy is done. Another option is an allogeneic stem cell transplant, where the stem cells are taken from a donor whose cells "match" those of the recipient. These cells are used in the same way, given to the patient after high dose chemotherapy. In both cases, bone marrow cells can re-grow from the stem cells. This enables a patient to tolerate the high doses of chemotherapy that work against Hodgkin lymphoma but have the unwanted side effect of wiping out healthy bone marrow.
Stem cell transplantation can sometimes cure patients when other treatment strategies have failed. However, stem cell transplantation is a complex and intense treatment, so it is typically reserved for patients who aren't cured with the initial treatment regimens of chemotherapy and/or radiation therapy.
Clinical trials are extremely important in furthering our knowledge of this disease. It is through clinical trials that we know what we do today, and many exciting new therapies are currently being tested. Talk to your healthcare provider about participating in clinical trials in your area. You can also explore currently open clinical trials using the OncoLink Clinical Trials Matching Service.
Follow-up Care and Survivorship
Once you have been treated for Hodgkin lymphoma, you will be followed closely by your care team. For the first two years after treatment, it is recommended you have a physical exam and complete blood counts every 3-6 months. After the first two years, you should see your care provider every 6-12 months until you are three years post-treatment, and annually thereafter. It is recommended you receive a CT scan of the chest, abdomen, and pelvis at 6, 12 and 24 months after completion of therapy. Survivors should also receive annual flu vaccines. If you received radiation to the spleen or had your spleen removed, you should receive pneumococcal, meningococcal, and H-flu revaccination 5-7 years after you have completed treatment.
Patients who are cured of their Hodgkin lymphoma can expect to live many decades after their treatment. However, this means that some late effects of treatments can be seen. These include:
- Secondary cancers: Other cancers, including lung and breast cancer, non-Hodgkin lymphoma and leukemia can occur, even many years after treatment for Hodgkin lymphoma. These depend on the type of treatment received and the location where radiation therapy may have been targeted. Your treatment team will discuss cancer screening plans with you after you have completed treatment.
- Cardiovascular disease: Patients who have received radiation to the mediastinum (chest) and certain kinds of chemotherapy may be at a higher risk for developing heart disease, sometimes 5 to 10 years after completion of treatment. Your team should monitor your blood pressure at all follow-up appointments. Your care team may also recommend a stress test or echocardiogram every 10 years after the completion of treatment.
- Hypothyroidism: Decreased thyroid function (hypothyroidism) has been reported in 50% of Hodgkin lymphoma survivors who also received radiation to their neck or chest. Your thyroid should be examined as part of your regular exams and thyroid function tests should be performed every year after treatment.
Fear of recurrence, the financial impact of cancer treatment, employment issues, and coping strategies are common emotional and practical issues experienced by Hodgkin lymphoma survivors. Your healthcare team can identify resources for support and management of these challenges faced during and after cancer.
Cancer survivorship is a relatively new focus of oncology care. With some 15 million cancer survivors in the US alone, there is a need to help patients transition from active treatment to survivorship. What happens next, how do you get back to normal, what should you know and do to live healthy going forward? A survivorship care plan can be a first step in educating yourself about navigating life after cancer and helping you communicate knowledgeably with your healthcare providers. Create a survivorship care plan today on OncoLink.
Resources for More Information
Leukemia and Lymphoma Society
Provides disease information and support resources. www.lls.org
Lymphoma Research Foundation
Offers education and patient services, information on research, co-pay assistance and stories of hope. www.lymphoma.org
American Society of Hematology
The official website of providers who treat blood disorders including Hodgkin lymphoma. www.hematology.org/Patients/Cancers/Lymphoma.aspx
Aims to bring people together around lymphoma-related issues by providing concise, up-to-date information and a meeting place for lymphoma patients and those who care about them. www.lymphomainfo.net
Adult Hodgkin Lymphoma Treatment (PDQ®). National Cancer Institute. October 2015. Retrieved from: http://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq#section/_57
Allen, T., & Razavi, G. S. E. (2016). Immunotherapy in Hodgkin Lymphoma. EC Cancer, 2, 93-99.
American Cancer Society. (2019). Key Statistics for Hodgkin Lymphoma. Retrieved from https://www.cancer.org/cancer/hodgkin-lymphoma/about/key-statistics.html.
Armand, P., Shipp, M. A., Ribrag, V., Michot, J. M., Zinzani, P. L., Kuruvilla, J., ... & Moskowitz, C. H. (2016). Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. Journal of Clinical Oncology, 34(31), 3733-3739.
Colpo A, Hochberg E and Chen Y. Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma. The Provider, 17, 80-90 (2012).
Darrington, D. L., & Vose, J. M. (2012). Appropriate surveillance for late complications in patients in remission from Hodgkin lymphoma. Current Hematologic Malignancy Reports, 7(3), 200-207.
Deng C, Pan B and O'Connor O. Brentuximab Vedotin. Clinical Cancer Research, 19:22. (2013).
Gunther, J. R., Fanale, M. A., Reddy, J. P., Akhtari, M., Smith, G. L., Pinnix, C. C., ... & Mawlawi, O. (2016). Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation. International Journal of Radiation Oncology* Biology* Physics, 96(1), 110-118.
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., Bierman, P. J., ... & Gordon, L. I. (2011). Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network, 9(9), 1020-1058.
Horn, S., Fournier-Bidoz, N., Pernin, V., Peurien, D., Vaillant, M., Dendale, R., ... & Kirova, Y. M. (2016). Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy. Cancer/Radiothérapie, 20(2), 98-103.
Iberri, D. J., Hoppe, R. T., & Advani, R. H. (2015). Hodgkin Lymphoma: The changing role of radiation therapy in early-stage disease–The role of functional imaging. Current Treatment Options in Oncology, 16(9), 1-13.
Kalac, M., Lue, J. K., Lichtenstein, E., Turenne, I., Rojas, C., Amengual, J. E., ... & Kuruvilla, J. (2016). Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. British Journal of Haematology.
Younes, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J. M., Ansell, S., ... & Cohen, J. B. (2016). Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. The Lancet Oncology, 17(9), 1283-1294.
Yung,L., Linch, D.(2003) Hodgkin's lymphoma. Lancet 361, 943-951; published online EpubMar 15 (10.1016/s0140-6736(03)12777-8).
National Comprehensive Cancer Network Guidelines Version 1.2017, https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf (login required)
SEER Cancer Stat Facts: Hodgkin Lymphoma. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/hodg.html